What is AptarGroup's pharma — D&A?

AptarGroup (ATR) reported pharma — D&A of $35.64M in Q1 2026.

How has AptarGroup's pharma — D&A changed year-over-year?

AptarGroup's pharma — D&A increased by 14.4% year-over-year, from $31.15M to $35.64M.

What does pharma — D&A mean?

The non-cash expense representing the systematic allocation of the cost of tangible and intangible assets over their useful lives. This reflects the ongoing consumption of the segment's capital base.

AptarGroup (ATR) Pharma — D&A — Quarterly & Annual

Screener

Other segment segments

Beauty

$24.72M+23.2%

Closures

$14.22M+4.8%

Similar metrics at other companies

IEPPharma — D&A

$2M-71.4%

CVSPharmacy & Consumer Wellness — D&A

$415M+6.7%

ADMAPlasma Collection Centers — D&A

$499K—

MYRGT&D — D&A

$15.92M+11.7%

TBLAD&A

$7.31M-21.7%

BCOD&A

$79.1M+32.3%

Other financials

Income statement

See full

Revenue$982.9M+10.8%

Gross profit$351.9M+4.6%

Operating income$107.5M-5.2%

Net income$72.7M-7.8%

EPS (diluted)$1.12-4.3%

Balance sheet

See full

Cash & equivalents$225.0M+78.8%

Total debt$1.4B+32.7%

Total equity$2.6B+3.6%

Total assets$5.1B+12.6%

Cash flow

See full

Operating cash flow$118.7M+43.5%

CapEx$65.4M+15.0%

Free cash flow$53.3M+106%

Valuation

See full

Market cap$8.69B-4.7%

Enterprise value$9.9B-2.2%

P/E22.5×-0.8×

P/S2.3×-0.3×

Profitability

See full

Gross margin36.7%-1.6pp

Operating margin12.8%-1.2pp

Net margin10%-0.4pp

FCF margin8.4%-2.1pp

Returns & leverage

See full

Return on equity15%-0.2pp

Debt / equity0.5×+0.1×

Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: AptarGroup’s 10-Q, filed May 1, 2026.

Filed: May 1, 2026, 11:22 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0000896622-26-000092

Three Months Ended March 31,	2026	2025
Depreciation and Amortization:
Pharma	$35,643	$31,148
Beauty	24,723	20,062
Closures	14,224	13,575
Depreciation and Amortization for Reportable Segments	74,590	64,785
Corporate & Other	1,135	862
Depreciation and Amortization	$75,725	$65,647
Capital Expenditures:

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is AptarGroup's pharma — D&A?: AptarGroup (ATR) reported pharma — D&A of $35.64M in Q1 2026.
How has AptarGroup's pharma — D&A changed year-over-year?: AptarGroup's pharma — D&A increased by 14.4% year-over-year, from $31.15M to $35.64M.
What does pharma — D&A mean?: The non-cash expense representing the systematic allocation of the cost of tangible and intangible assets over their useful lives. This reflects the ongoing consumption of the segment's capital base.